| Ignite Injectable Cellular Scaffold
Repair Stimulus for Stable
Nonunions and Problem Fractures
The IGNITE® ICS Biocomposite is a repair
stimulus that combines demineralized bone matrix (DBM) and
bone marrow aspirate (BMA) for percutaneous treatment of stable
nonunions and problem fractures. The Biocomposite graft has
demonstrated comparable results to standard, open autologous
grafting, but with distinct advantages:
IGNITE® ICS Graft
vs. Open Autologous Grafting
• Lower Morbidity -- Minimally Invasive Aspiration &
Injection
• High Demonstrated Clinical Efficacy -- 61/69 Stable
Nonunions Healed
(88%) Using A DBM/BMA Composite
• Reduced OR Time -- Average Procedure Time <30 Minutes
• Lower Cost Of Treatment -- Iliac Crest Harvest Estimated
Between $2,200 and $5,000
Picture 1 | Hematoma Phase
The IGNITE® ICS Graft is injected to induce hematoma
formation. Osteogenic stem cells are transplanted to the defect
site.
Picture 2 | Inflammatory Phase
The fracture hematoma clots and elicits a transient inflammatory
response. Angiogenisis is an early, critical component at
this stage of healing.
Picture 3 | Soft Callus Phase
Tissue becomes more organized as new bone (osteoid) is laid
down.
Picture 4 | Hard Callus & Remodeling Phase
Tissues continue to organize as osteoid is calcified. Remodeling
completes the reparative phase as the bone is stressed.
Essentially a "surgeon-induced fracture
hematoma", the IGNITE® ICS Biocomposite Graft reinforces
and stimulates cellular activity to stimulate fracture healing
in poorly vascularized areas, such as the long bone diaphysis.
Healing with the IGNITE® ICS Graft proceeds via the normal
stages of fracture healing.
For more information on the Ignite Injectable
Cellular Scaffold such as brochures, articles, video etc.,
please contact Ortotech
directly or visit the official homepage
http://www.wmt.com/Physicians/Products/Biologics/
IGNITEICSInjectableCellularScaffold.asp
  
|
